This post was originally published on this site The U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to Mateon‘s OT101 as a therapy for diffuse intrinsic pontine glioma (DIPG), a difficult-to-treat brain tumor that affects children. The designation is designed to accelerate the development of therapies that can improve the management of…
This post was originally published on this site The U.S. Food and Drug Administration has approved Mylan‘s generic version of AstraZeneca‘s Faslodex injection to be used for the same breast cancer indications as the original product, the company announced. The approval makes Mylan‘s Fulvestrant injection the third generic version of Faslodex, following the approval of…
This post was originally published on this site Eating mushrooms frequently — three times a week or more — may have a reduced risk of prostate cancer compared to those eating mushrooms less than once a week, a study of Japanese men found. The association holds true only for men 50 or older, according to…
This post was originally published on this site Xynomic Pharmaceutical‘s abexinostat has received Fast Track Designation by the U.S. Food and Drug Administration (FDA) as a fourth-line treatment for follicular lymphoma, the company announced in a press release. The decision comes after Xynomic applied for the designation at the beginning of August. The FDA grants…
This post was originally published on this site Spherix announced that it has closed an exclusive option agreement to license PrAg-PAS, an anthrax-based potential therapy for ovarian cancer developed by scientists at the University of Maryland at Baltimore (UMB). The agreement gives Spherix rights to a patent application, now under consideration by the U.S. Patents Trademark…
This post was originally published on this site CT053, a novel cell-based therapy being developed by Carsgen Therapeutics, was given priority medicines (PRIME) status by the European Medicines Agency (EMA) as a potential treatment of relapsed or refractory multiple myeloma. Early findings from a Phase 1 trial in people with heavily pre-treated disease support the therapy’s…
This post was originally published on this site The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended that a combination of Bavencio (avelumab) and Inlyta (axitinib) be approved for the first-line treatment of adults with advanced renal cell carcinoma, the most common form of kidney cancer.…
This post was originally published on this site Because access to prior mammograms is critical for women during all stages of breast health, Life Image is offering free membership during October — Breast Cancer Awareness Month — to its unique health management platform. At the same time, the global network for sharing clinical and imaging…
This post was originally published on this site Sarcoidosis patients and their partners experience a lower quality of life because of nonspecific disease-associated symptoms compared to healthy people, a new study demonstrated. The study, titled “Quality of Life of Couples Living with Sarcoidosis,” was published in the journal Respiration. Sarcoidosis is an inflammatory disease affecting…
This post was originally published on this site Fate Therapeutics has been cleared by the U.S. Food and Drug Administration (FDA) to initiate clinical studies evaluating FT596, its off-the-shelf cell-based immunotherapy designed to target multiple tumor proteins. The company plans to start testing FT596 for the treatment of B-cell lymphoma and chronic lymphocytic leukemia, either…
